We Accelerate Discovery

You are here


Program Snapshot

Part of the Common Fund's High-Risk, High-Reward Research Program, the Pioneer Award supports individual scientists of exceptional creativity, who propose pioneering and transforming approaches to major challenges in biomedical and behavioral research.


Read more


HIV Latency Confers Evolutionary Advantage

HIVLeor Weinberger, 2013 Pioneer and 2009 New Innovator Awardee, published back-to-back papers in Cell that demonstrate HIV latency is caused by the virus itself, rather than by the immune cells as was previously thought. His work suggests latency is a naturally selected tactic employed by the virus to increase infection rates and provides important information about how and why latency is established and maintained. Weinberg’s work on latency opens the door to novel therapeutic approaches to treat HIV infection.
Read more

Measuring Individual Molecules

HIVMichael Roukes, a 2010 awardee, published a paper in Nature Nanotechnology demonstrating a new methodology enabling the simultaneous measurements of mass, position and molecular size, and shape of individual analytes as they adsorb onto a nanomechanical resonator. The imaging technique can enable single-molecule mass spectrometry and the evaluation of the size and shape of individual molecules in the nanometric-scale.
Read more

New Device Holds Promise for Hard-to-Reach Tumors

Dr. Joseph DeSimone, a 2009 awardee, developed a device that can be implanted directly on a cancer tumor to precisely deliver doses of chemotherapy drugs with minimal spreading to surrounding cells. The device will revolutionize the treatment of the most challenging types of cancer that enmesh themselves with healthy tissue and blood vessels.
Read more


Application Information

•  Open to all career stages
•  Reference Letters required
•  Minimum of 51% research effort
•  Awards up to $500K per year for up to 5 years
•  More information
Application Status
FY 2015 Applications Under Review
FY 2016 RFA-RM-13-006
Due October 9, 2015


Karl Deisseroth (2005 Pioneer and 2012 Transformative Researcher) receives the FNIH 2015 Lurie Prize Exit Disclaimer for his work on optogenetics. Dr. Desisseroth also received the Carnegie Mellon's Dickson Prize in Science  Exit Disclaimer and the 2014 Keio Medical Science Prize Exit Disclaimer for his revolutionary work in optogenetics and his work on CLARITY, converting tissue into a gel linked to polymers that allow transparency and high-resolution optical access.

Karl Deisseroth (2005 Pioneer and 2012 Transformative Researcher) and Xiaoliang Sunney Xie (2004 and 2013 Pioneer and 2009 and 2010 Transformative Researcher) win the prestigious Albany Prize. Exit Disclaimer Dr. Desisseroth is honored for his role in developing optogenetics. Dr. Xie is recognized for his pioneering work in single-molecule biophysical chemistry and its application to biology.

   Agenda  •  Abstracts  •  Videocasts from Day 1Day 2, and Day 3

Save the date for the 2015 High-Risk, High-Reward Research Symposium on December 7-9 at Natcher Conference Center, NIH, Bethesda, MD!
Up to Top